Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Duarte

Showing results (801-810 of 824) with videos related to

Pageof 83
Sort By:
Transfusion|July 11, 2025
ABO-mismatched platelet and plasma transfusion practices and the potential for transfusion-related alpha-gal syndrome: The Biomedical Excellence for Safer Transfusion Collaborative StudyNancy M Dunbar, Richard M Kaufman, Karina S Bary, et al.
Immunobiology|June 6, 2019
A biomarker for tegumentary and visceral leishmaniasis based on a recombinant Leishmania hypothetical proteinDaniela P Lage, Amanda S Machado, Fernanda F Ramos, et al.
Molecular Immunology|December 31, 2018
Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infectionPatrícia A F Ribeiro, Daniel S Dias, Daniela P Lage, et al.
Parasitology International|February 7, 2018
Serological diagnosis and prognostic of tegumentary and visceral leishmaniasis using a conserved Leishmania hypothetical proteinDaniel S Dias, Patrícia A F Ribeiro, Beatriz C S Salles, et al.
Parasitology|September 11, 2018
High-through identification of T cell-specific phage-exposed mimotopes using PBMCs from tegumentary leishmaniasis patients and their use as vaccine candidates against Leishmania amazonensis infectionGerusa B Carvalho, Lourena E Costa, Daniela P Lage, et al.
Cellular Immunology|August 23, 2020
A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasisJoão A Oliveira-da-Silva, Amanda S Machado, Fernanda F Ramos, et al.
Molecular Immunology|February 2, 2023
Recombinant endonuclease III protein from Leishmania infantum associated with Th1-type adjuvants is immunogenic and induces protection against visceral leishmaniasisDaniela P Lage, Amanda S Machado, Camila S Freitas, et al.
Experimental Parasitology|March 21, 2024
Treatment using vanillin-derived synthetic molecules incorporated into polymeric micelles is effective against infection caused by Leishmania amazonensis speciesIsabela A G Pereira, Camila S Freitas, Raquel S B Câmara, et al.
Cytokine|February 19, 2024
New synthetic molecules incorporated into polymeric micelles used for treatment against visceral leishmaniasisCamila S Freitas, Isabela A G Pereira, Daniela P Lage, et al.
Lupus|February 23, 2011
The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practiceM Mosca, M Govoni, P Tomietto, et al.
Pageof 83

Showing results (801-810 of 824) with videos related to

Sort By:
Pageof 83
Transfusion|July 11, 2025
ABO-mismatched platelet and plasma transfusion practices and the potential for transfusion-related alpha-gal syndrome: The Biomedical Excellence for Safer Transfusion Collaborative StudyNancy M Dunbar, Richard M Kaufman, Karina S Bary, et al.
Immunobiology|June 6, 2019
A biomarker for tegumentary and visceral leishmaniasis based on a recombinant Leishmania hypothetical proteinDaniela P Lage, Amanda S Machado, Fernanda F Ramos, et al.
Molecular Immunology|December 31, 2018
Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infectionPatrícia A F Ribeiro, Daniel S Dias, Daniela P Lage, et al.
Parasitology International|February 7, 2018
Serological diagnosis and prognostic of tegumentary and visceral leishmaniasis using a conserved Leishmania hypothetical proteinDaniel S Dias, Patrícia A F Ribeiro, Beatriz C S Salles, et al.
Parasitology|September 11, 2018
High-through identification of T cell-specific phage-exposed mimotopes using PBMCs from tegumentary leishmaniasis patients and their use as vaccine candidates against Leishmania amazonensis infectionGerusa B Carvalho, Lourena E Costa, Daniela P Lage, et al.
Cellular Immunology|August 23, 2020
A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasisJoão A Oliveira-da-Silva, Amanda S Machado, Fernanda F Ramos, et al.
Molecular Immunology|February 2, 2023
Recombinant endonuclease III protein from Leishmania infantum associated with Th1-type adjuvants is immunogenic and induces protection against visceral leishmaniasisDaniela P Lage, Amanda S Machado, Camila S Freitas, et al.
Experimental Parasitology|March 21, 2024
Treatment using vanillin-derived synthetic molecules incorporated into polymeric micelles is effective against infection caused by Leishmania amazonensis speciesIsabela A G Pereira, Camila S Freitas, Raquel S B Câmara, et al.
Cytokine|February 19, 2024
New synthetic molecules incorporated into polymeric micelles used for treatment against visceral leishmaniasisCamila S Freitas, Isabela A G Pereira, Daniela P Lage, et al.
Lupus|February 23, 2011
The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practiceM Mosca, M Govoni, P Tomietto, et al.
Pageof 83